The treat-to-target (T2T) concept has improved outcomes for patients with diabetes,
hypertension and rheumatoid arthritis. This therapeutic strategy involves choosing a well …

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the
recommendations by international medical associations including EULAR and the ACR, is …

Our objective was to update the EULAR recommendations for the management of systemic
lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic …

Objective To achieve consensus on a definition of remission in SLE (DORIS). Background
Remission is the stated goal for both patient and caregiver, but consensus on a definition of …

Objectives Open-labelled clinical trials suggested that low-dose IL-2 might be effective in
treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled …

Objectives Type-I interferons (IFNs-I) have potent antiviral effects. IFNs-I are also
overproduced in patients with systemic lupus erythematosus (SLE). Autoantibodies (AAbs) …

Obtaining an updated view of the epidemiology, risk factors, and prognosis of systemic lupus
erythematosus (SLE) is pivotal to our understanding of the disease burden. Recent …

Systemic lupus erythematosus (SLE), a complex and heterogeneous autoimmune disease,
represents a significant challenge for both diagnosis and treatment. Patients with SLE in …

Background Treat-to-target strategies have improved outcomes in single-organ diseases
with simple clinical or laboratory endpoints. A lack of validated endpoints has prevented …

Objective To determine the independent impact of different definitions of remission and low
disease activity (LDA) on damage accrual. Methods Patients with≥ 2 annual assessments …